Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease
- 1 February 2020
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (4) , 643-650
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis PatientsJACC, 2014
- Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal FunctionJACC, 2013
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection FractionJAMA, 2012
- Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart FailureJACC, 2012
- Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practiceEuropean Heart Journal, 2012
- The Ubiquitous Mineralocorticoid Receptor: Clinical ImplicationsCurrent Hypertension Reports, 2012
- Potential impact of optimal implementation of evidence-based heart failure therapies on mortalityAmerican Heart Journal, 2011
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney diseaseKidney International, 2011
- Use of Aldosterone Antagonists in Heart FailureJAMA, 2009